PDCD1 and esophageal squamous cell carcinoma: There were three studies reported on the treatment efficacy of combination immunotherapy in advanced ESCC patients who progressed prior to immunotherapy (PD‐1 inhibitor combined with anti‐angiogenesis therapy: two studies; PD‐1 inhibitor combined with chemoradiotherapy: one study).